OSU-03012 - Wikipedia, the free encyclopedia
https://en.wikipedia.org/wiki/OSU-03012 Proxy Highlight
OSU-03012 (AR-12) is a celecoxib derivative with anticancer and anti-microbial activity. Unlike celecoxib, OSU-03012 does not inhibit COX, but inhibits several other important enzymes instead which may be useful in the treatment of some forms of cancer, while also having antifungal activity via disruption of ... The European Commission has designated AR-12 as an orphan drug for ...
AR-12 - Arno Therapeutics, Inc.
www.arnothera.com/ar12.html Proxy Highlight
AR-12. Drug Description AR-12 is a potentially first-in-class, orally available, targeted anti-cancer agent that has been shown in preclinical studies to inhibit ...
Arno Therapeutics to Inhibit Cancer and Enhance Portfolios: CEO Alexander Zukiwski [ARNI]
TLSR: What can you tell me about Arno’s third compound, AR-12?
AZ: There is evidence that AR-12 hits the glucose-regulated protein 78 (GRP 78) chaperone. This is a master regulator of unfolded protein response. For normal cells, it doesn’t cause any major toxicity, but it has tremendous potential activity against various diseases. In addition, AR-12 inhibits heat shock protein (Hsp) 70 and Hsp 90 chaperones. Our colleagues at OSU demonstrated that AR-12 also induces and enhances autophagy in host effector cells.
“We are optimistic that AR-42 could have activity in different solid tumors.”
Through a series of collaborations, AR-12 was shown to have in vitro activity against various microbial pathogens. What is exciting is that this novel mechanism of action potentially allows for development of a host-targeted antimicrobial agent. By targeting host cells instead of microbes, AR-12 may not be subject to typical drug resistance mechanisms reported for certain antiviral agents and antibiotics. We are currently developing a series of collaborations to further explore the potential of AR-12 in the antimicrobial space.
TLSR: What disease targets are of interest for your first studies?
AZ: AR-12 has published activity against certain fungal species. Furthermore, our colleagues from Virginia Commonwealth University have recently published data demonstrating AR-12 to have activity against a series of viruses and antibiotic-resistant bacteria. Before selecting disease targets, we want to understand the spectrum of activity. Next, we intend to focus development on those areas deemed to have the highest likelihood of success, and where there is a clear medical need.
TLSR: What are the catalysts or milestones that investors should look for with respect to each of your compounds?
AZ: First will be completion of the onapristone Phase 2 study in recurrent and metastatic endometrioid cancer. For AR-42, we are looking for an increasing amount of data from the Phase 2 studies in various tumor types. For AR-12, being at an opportunistic phase, we are determining the best avenue for development in the infectious disease space. All of these are possible over the next two years.
Virginia Commonwealth University
Go Rams!
5.56mm
Makes sense.